Virax Biolabs Group Limited Or short interest was 71.68% of the float on April 15th, according to new data we received from Benzinga. Short interest totaled 5,006,970 shares, which was an increase of 2,372,871.56% from March 31st.
It is estimated that it would take 1.0 days for short sellers to buy back their shares, with current trading volumes.
Virax Biolabs Group Limited Or Hedge Fund Activity
We have seen 3 institutional investors add shares of Virax Biolabs Group Limited Or stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP removed 60,073 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $20,773
- XTX TOPCO LTD added 21,437 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,412
- VIRTU FINANCIAL LLC removed 21,376 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $7,391
- UBS GROUP AG added 4,132 shares (+123.0%) to their portfolio in Q4 2025, for an estimated $1,428
- NATIONAL BANK OF CANADA /FI/ removed 4,000 shares (-40.0%) from their portfolio in Q4 2025, for an estimated $1,383
- OSAIC HOLDINGS, INC. added 20 shares (+inf%) to their portfolio in Q4 2025, for an estimated $6
- FARTHER FINANCE ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q1 2026, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Virax Biolabs Group Limited Or Analyst Ratings
Wall Street analysts have issued reports on $VRAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
To track analyst ratings and price targets for Virax Biolabs Group Limited Or, check out Quiver Quantitative's $VRAX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
